Advertisement

Topics

Companies Related to "Modified viruses deliver death antibiotic resistant bacteria" [Most Relevant Company Matches] RSS

10:57 EDT 20th September 2018 | BioPortfolio

Here are the most relevant search results for "Modified viruses deliver death antibiotic resistant bacteria" found in our extensive corporate database of over 50,000 company records.

Showing "Modified viruses deliver death antibiotic resistant bacteria" Companies 1–25 of 2,000+

Extremely Relevant

Pharmaceutica Limited

Pharmaceutica Limited is a privately owned pharmaceutical company founded in March 2003, to discover and develop a new generation of anti-infective drug technologies that combat the increasing problem caused by the rapid evolution of resistance by pathogenic organisms. The company is targeting both human and veterinary applications for its technologies.The initial focus is to find a solution to th...


AdvanDx, Inc

AdvanDx announces that at the recent American Society for Microbiology (ASM) meeting in Orlando, Florida, EVIGENE™ kits for detecting specific antibiotic resistance, virulence, and toxicity markers such as methicillin-resistance, vancomycin-resistance, PVL and TSST-1 in Staphylococcus aureus and enterococci, were launched for research use only in the United States. EVIGENE was officially launch...

Lysando AG

Lysando AG is a technology leader in the area of antimicrobial proteins. Since its foundation in 2009, the privately financed research company has done research on artificial designer proteins with a team of scientists in the town of Regensburg. Artilysin®s represent a revolutionary breakthrough in the battle against multi-resistant bacteria. With this ...


Microbiotix, Inc.

Microbiotix, Inc. is a privately held, product-focused biopharmaceutical company engaged in the research and development of novel small molecule, anti-infective drugs that address commercially significant medical markets. The company currently has four novel compound series in research and development. Microbiotix currently has in development MBX 500, the first antibiotic that targets the DNA po...

Special Phage Services

Few inventions in science and medicine have had such a profound effect on human health as the discovery and subsequent development of antibiotics. Following their introduction during World War II many dreaded infectious diseases such as diphtheria, pneumonia, syphilis, and tuberculosis disappeared almost overnight. However all is not well with the antibiotics story. The bacterial pathogens are f...

Relevant

Lakewood-Amedex Inc.

Lakewood-Amedex is a privately held development-stage biopharmaceutical company with a broad patent portfolio of inventions, including, 24 granted and/or issued patents and 45 patent applications covering its proprietary NuBiotics family of anti-microbial products, proven to be effective against a wide range of bacteria, encompassing antibiotic resistant strains including methicillin-resistant Sta...

Lakewood-Amedex, Inc.

Lakewood-Amedex is a privately held development-stage biopharmaceutical company with a broad patent portfolio of inventions, including, 24 granted and/or issued patents and 45 patent applications covering its proprietary NuBiotics family of anti-microbial products, proven to be effective against a wide range of bacteria, encompassing antibiotic resistant strains including methicillin-resistant Sta...

Phage Biotech Ltd.

Phage-Biotech Ltd. was incorporated in March 2000, as a new player in the emerging field of Phage Therapy. The Company’s mission is to develop proprietary Phage-based anti-infective therapeutics to combat the increasing number of antibiotic-resistant infections worldwide. The Company has two short-term strategic objectives:To identify and formulate proprietary topical Phage preparations from dis...

ConjuGon

The rise of drug-resistant strains of pathogenic bacteria is quickly becoming a health problem of potentially crisis proportions. Virtually all experts agree that entirely new approaches are needed to go beyond the use of traditional antibiotics. Fundamentally new, even radical, anti-microbial agents are necessary to kill pathogenic bacteria while minimizing the ability of the bacteria to develop ...

Mpex Pharmaceuticals

Mpex Pharmaceuticals is focused on the discovery and development of new anti-bacterial drugs that meet the growing clinical need created by multi-drug resistant bacterial pathogens. It is well documented that antibiotic resistance is a growing, serious problem in both the hospital and community setting. Mpex's approach is to improve the activity of existing antibiotics by utilizing methods and pot...

iDiverse, Inc

iDiverse is a biotechnology company focused on developing and commercializing transgenic plants that simultaneously resist a broad spectrum of diseases and environmental stresses – all with the addition of only one proprietary sequence.We believe that genetically modified plants incorporating our ProTectAll™ transgenic technology will be resistant to a wide range of fungi and viruses. They wil...

DNAtrix Inc.

DNAtrix is a company developing modified oncolytic viruses for the treatment of the most aggressive forms of cancer. Since viruses are already efficient at killing cells, scientists have harnessed this ability by modifying a common cold virus so that it targets and selectively kills cancer cells. DNAtrix is a privately held company with offices located in ...

Viroblock SA

Viroblock is dedicated to developing and commercializing a new generation of anti-viral products with a novel mechanism of action against enveloped viruses. Enveloped viruses represent more than 60% of all existing viruses and include major human pathogens such as human and avian influenzas, the hepatitis B and C viruses and the AIDS virus.

Oculus Innovative Sciences, Inc.

Oculus Innovative Sciences is a commercial medical technology company that designs, produces and markets safe and effective tissue care products based upon the Microcyn® Technology platform, which significantly reduces the need for antibiotics while reducing infections and accelerating healing. The Microcyn Technology addresses the need for improved sol...

NEOSPORIN(R)

NEOSPORIN® Original First Aid Antibiotic Ointment, from the #1 Doctor-recommended brand, provides long-lasting infection protection and kills more types of infectious bacteria in laboratory tests than even the leading topical prescription antibiotic. Plus, NEOSPORIN® Original First Aid Antibiotic Ointment and a bandage help heal minor wounds four days faster than a bandage alone and may help min...

Cytovax Biotechnologies Incorporated

Cytovax Biotechnologies Inc. is a biotechnology company focused on the development of novel approaches for the prevention and treatment of infectious diseases.Cytovax is developing new, effective weapons in the fight against infectious diseases. Cytovax's products act through a mechanism that is different from that of current anti-infectives, such as antibiotics, which are designed to kill bacteri...

SIGA Technologies

SIGA Technologies is applying bacterial genomics in the design and development of novel products for the prevention and treatment of serious infectious diseases. With broad technology platforms in both vaccines and antibiotics, SIGA's product development programs emphasize the increasingly serious problem of drug resistant bacteria. SIGA's lead product programs focus on: Mucosal vaccines against ...

Achillion Pharmaceuticals

Achillion is a privately held pharmaceutical company focused on the discovery, development and commercialization of innovative small molecule drugs that combat drug resistance in infectious diseases, with a particular emphasis on antiviral drugs to treat diseases caused by hepatitis B and C viruses (HBV and HCV), HIV and herpes viruses.Product Candidate PortfolioThe Company’s broad drug developm...

Filligent

In 2008, Filligent developed a revolutionary technology, called BioFriend(TM), which kills viruses and bacteria on contact. BioFriend's molecular technology can be applied to substrates such as rayon and cotton textile fiber. BioFriend(TM) captures pathogens by mimicking the sites on human cells to which they normally attach, then, destroys them by disrupting their surfaces (viruses) and cell ...

Synspira

Synspira is developing a new class of inhalable glycopolymer-based therapeutics that disrupt mucus accumulation and biofilm invasion, which are key drivers of pulmonary diseases including cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD), and pneumonia. Synspira has an exclusive license from Synedgen to the Glycomics Technology Platform fo...

Virus Detection & Diagnostics Virinova

Our unique and proprietory diagnostic technology enables the detection and quantification of viruses without the use of PCR or antibodies - Direct detection of viruses and viral particles - Fast and simple - Suitable for known and unknown viruses Areas of application:Diagnosis and monitoring of viral infections - Known and unknown virusesProcess control in biotechnology - No...

DNAtrix, Inc.

DNAtrix is a privately held company developing modified viruses for treating cancer. The company has offices located in Houston, Texas and San Diego, California. For more information, please visit the company website at http://www.dnatrix.com.

Mpex Pharmaceuticals, Inc.

Mpex Pharmaceuticals is a clinical stage biopharmaceutical company whose mission is to develop important new therapies to combat the growing issue of antibiotic resistance. The company's internal development pipeline focuses on combining proprietary formulations, PK/PD strategies and novel potentiating agents with proven antibiotics to overcome or directly inhibit the molecular mechanisms in bacte...

Telephus Medical LLC

Telephus Medical, located in San Diego, California, is developing a suite of monoclonal antibody products designed to neutralize key staphylococcal enzymes used to attach to host tissues, replicate and evade immune attack. These enzymes, are central components of the bacterial machinery staphylococci utilize to invade host tissues, evade the immune respons...

Innogenetics Biologicals

The one-stop-shop for cGMP-compliant Manufacturing, Fill & Finish of Antigens, Bacteria, Viruses and Vaccines. Our Philosophy is to be "Transparent with your Time and Money". Expertise : • Extensive experience with cell-line and process development for manufacturing of proteins, fusion constructs and “recombinant” viruses • Production of your biologicals of interest in a variety of bac...


More From BioPortfolio on "Modified viruses deliver death antibiotic resistant bacteria"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks